128 results
6-K
EX-99.1
GLPG
Galapagos NV
30 May 24
Current report (foreign)
4:44pm
are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update
6-K
EX-99.1
GLPG
Galapagos NV
16 May 24
Current report (foreign)
8:11am
contained herein are based on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
on management’s current expectations and beliefs and speak only as of the date hereof, and Galapagos makes no commitment to update or publicly release
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
report Our Sustainability Commitment – Forward, Sustainably 82 Our Ambition 83 Our Sustainability Governance 84 Our Double Materiality Assessment 84 … future challenges.
Sustainability report Our commitment to society: Forward, Sustainably Pioneering science to transform patient outcomes
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
. The Remuneration Committee believes this demonstrates a clear commitment to better align with market practice and views from shareholders gathered during our … of the Executive Committee members with those of shareholders and demonstrate their commitment, the existing share ownership requirements will be doubled
6-K
EX-99.9
t8u6k7tb xi
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.5
62ovr7eavg085otsqvce
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.14
lzkh9q04uoh3c
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.4
7ahwro w7v0x1mk83
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.3
ycvb3h4ywoexrv7e1d
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.1
3zxfgqa0mgrs
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
fyhujvj0
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
EX-99.1
rxriylrtbzi3v p4
4 Jan 24
Current report (foreign)
5:32pm
6-K
EX-99.1
krgt7kf bcid5om6
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
EX-99.1
bjdspfw b4
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
EX-99.1
l9icy7 q3
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
itzcby
12 Dec 23
Current report (foreign)
6:00am
S-8
EX-4.1
njmj 4d6kl9qvpvc1mbd
4 Dec 23
Registration of securities for employees
5:16pm
6-K
EX-99.1
8rzqq9fo7tseolz sbc
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am